Six-month response to delamanid treatment in MDR-TB patients

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR-TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR-TB. Results show good tolerability and treatment response at 6 months.

To read the full study, click here.

Source: Emerging Infectious Disease